Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst ...

One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...